Overview
Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical mRNA engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today.
Basic Stats
The share price of Jasper Therapeutics, Inc. as of September 5, 2025 is $2.73 / share. This is a decrease of -2.50% from the prior week. The market cap (or net worth) of Jasper Therapeutics, Inc. as of September 5, 2025 is $44.28 MM.
The Factor Analysis chart (below right) shows a view of Jasper Therapeutics, Inc. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 44.28 MM |
| EV | 4.77 MM |
| Shares Out. | 16.22 MM |
| Earnings Date | |
| EPS (TTM) | -5.61 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 2.48 |
| Short Shares Avail. | 0.40 MM |
| Short Interest | 1.23 MM |
| Short Float | 11.01 % |
| Days to Cover | 9.17 days |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | -85.74 % |
| Volatility (1 yr) | 1.14 |
| Beta | 2.07 |
| Sharpe Ratio (1 yr) | -0.79 |
| Sortino Ratio (1 yr) | -0.99 |
| PE Ratio | -0.49 |
| Price/Book | 1.88 |
| Price/TBV | 1.88 |
| Book/Market | 0.53 |
| EBIT/EV | -19.07 |
| EBIT(3yr avg)/EV | -14.59 |
| ROA | -0.80 |
| ROE | -0.91 |
| ROIC | -3.54 |
| CROIC | -2.62 |
| OCROIC | -2.86 |
| Implied Volatility | 179.46 % |
| Put/Call OI Ratio | 0.13 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Jasper Therapeutics, Inc. is $15.45. The forecasts range from a low of $4.04 to a high of $26.25. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Jasper Therapeutics, Inc.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-11-14 | Oppenheimer | Outperform | Maintains | |
| 2022-11-01 | EF Hutton | Buy | Initiate | |
| 2022-07-13 | Credit Suisse | Outperform | Maintains | |
| 2022-05-13 | Credit Suisse | Outperform | Maintains | |
| 2022-02-28 | Cantor Fitzgerald | Overweight | Initiate | |
| 2022-02-25 | Credit Suisse | Outperform | Maintains | |
| 2021-11-08 | Credit Suisse | Outperform | Initiate | |
| 2021-10-21 | William Blair | Outperform | Initiate | |
| 2021-10-20 | BMO Capital | Outperform | Initiate | |
| 2021-10-13 | Oppenheimer | Outperform | Initiate | |
| 2023-01-11 | EF Hutton | Buy | Maintains | |
| 2023-01-11 | Credit Suisse | Outperform | Maintains | |
| 2023-02-07 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2023-02-16 | EF Hutton | Buy | Maintains | |
| 2023-02-17 | EF Hutton | Buy | Reiterate | |
| 2023-02-21 | EF Hutton | Buy | Reiterate | |
| 2023-02-27 | EF Hutton | Buy | Reiterate | |
| 2023-03-09 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2023-03-09 | EF Hutton | Buy | Reiterate | |
| 2023-03-09 | Credit Suisse | Outperform | Reiterate | |
| 2023-05-16 | Oppenheimer | Outperform | Outperform | Reiterate |
| 2023-05-15 | Credit Suisse | Outperform | Outperform | Reiterate |
| 2023-05-15 | EF Hutton | Buy | Buy | Reiterate |
| 2023-06-12 | EF Hutton | Buy | Buy | Reiterate |
| 2024-03-28 | RBC Capital | Outperform | Initiate | |
| 2023-08-14 | Credit Suisse | Outperform | Outperform | Reiterate |
| 2023-08-11 | Capital One | Overweight | Initiate | |
| 2023-10-12 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2024-03-18 | TD Cowen | Outperform | Initiate | |
| 2024-05-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-15 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-04-03 | Evercore ISI Group | Outperform | Initiate | |
| 2024-05-06 | HC Wainwright & Co. | Buy | Initiate | |
| 2024-03-07 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-06-27 | Stifel | Buy | Initiate | |
| 2024-07-08 | BTIG | Buy | Initiate | |
| 2024-06-18 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2024-09-27 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-02-13 | UBS | Buy | Initiate | |
| 2024-08-14 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-08-26 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2025-05-13 | UBS | Buy | Buy | Maintains |
| 2025-01-09 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-01-10 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-08-05 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-10 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-12-23 | RBC Capital | Outperform | Outperform | Reiterate |
| 2024-09-09 | JMP Securities | Market Outperform | Initiate | |
| 2024-10-24 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-12-06 | BMO Capital | Outperform | Initiate | |
| 2025-01-06 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-10-15 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-13 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-03-11 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-09 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2024-10-15 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-05-15 | Oppenheimer | Outperform | Outperform | Maintains |
| 2025-08-15 | UBS | Buy | Buy | Maintains |
| 2025-07-08 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2025-07-08 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2025-07-08 | BMO Capital | Outperform | Market Perform | Downgrade |
| 2025-07-07 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2025-07-07 | William Blair | Outperform | Market Perform | Downgrade |
| 2025-07-07 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| 2025-07-07 | BTIG | Buy | Buy | Maintains |
